Get started
Author

Maja Preložnik Navodnik

Observed names: Maja Navodnik Preložnik, Navodnik Preloznik, Maja, Navodnik Preložnik, Maja
Observed institution: Splošna Bolnišnica Celje
ORCID: 0009-0007-5629-2646
Observed ORCID: 0009-0007-5629-2646
OpenAlex ID: A5092469528
The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
2023 · Maja Preložnik Navodnik, Andrej Janež, et al. · Pharmaceutics · 31
PDF
A randomized, placebo-controlled study of chitosan gel for the treatment of chronic diabetic foot ulcers (the CHITOWOUND study)
2024 · Matevž Slivnik, Maja Navodnik Preložnik, et al. · BMJ Open Diabetes Research & Care · 25
Adjuvant Treatment with Empagliflozin or Semaglutide Increases Endothelial Progenitor Cells in Subjects with Well-Controlled Type 1 Diabetes Mellitus
2025 · Maja Preložnik Navodnik, Katarina Reberšek, et al. · Current Issues in Molecular Biology · 4
PDF
P149 - ECE_2587 - Semaglutide and empagliflozin improve glycaemic control and body composition in type 1 diabetes (T1DM): results from the ENDIS trial
2026 · Maja Navodnik Preložnik, Aleksandra Šauperl · European Journal of Endocrinology
PDF
ffect of empagliflozin or semaglutide on endothelial function and arterial stiffness, other clinical parameters and laboratory biomarkers in type 1 diabetic subjects
2025 · Navodnik Preložnik, Maja · University of Maribor digital library (University of Maribor)
PDF
Works count: 6
Citation count: 60
H-index: 3
I10-index: 2
Year
Topic
Type